8月11日，沪深两融数据显示，英诺特获融资买入额0.23亿元，居两市第844位，当日融资偿还额0.21亿 元，净买入175.30万元。 本文源自：金融界 作者：智投君 最近三个交易日，7日-11日，英诺特分别获融资买入0.18亿元、0.15亿元、0.23亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 ...

Group 1 - The core point of the article highlights the financing activities of Innotec, indicating a financing buy amount of 0.15 billion yuan on August 8, ranking it 1000th in the market [1] - Over the last three trading days from August 6 to August 8, Innotec received financing buy amounts of 0.12 billion yuan, 0.18 billion yuan, and 0.15 billion yuan respectively [1] - On the same day, the financing repayment amount was 0.17 billion yuan, resulting in a net sell of 2.61 million yuan [1] Group 2 - In terms of securities lending, there were no shares sold or net sold on that day, indicating no activity in this area [2]

8月7日，沪深两融数据显示，英诺特获融资买入额0.18亿元，居两市第945位，当日融资偿还额0.23亿 元，净卖出486.33万元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 本文源自：金融界 最近三个交易日，5日-7日，英诺特分别获融资买入0.15亿元、0.12亿元、0.18亿元。 作者：智投君 ...

8月5日，沪深两融数据显示，英诺特获融资买入额0.15亿元，居两市第987位，当日融资偿还额0.11亿 元，净买入377.28万元。 本文源自：金融界 作者：智投君 最近三个交易日，1日-5日，英诺特分别获融资买入0.15亿元、0.14亿元、0.15亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 ...

Group 1 - The core point of the article highlights the financing activities of Innotec, with a financing buy amount of 0.16 billion yuan on July 31, ranking 1062nd in the market [1] - Over the last three trading days (July 29-31), Innotec received financing buy amounts of 0.14 billion yuan, 0.18 billion yuan, and 0.16 billion yuan respectively [1] - On the same day, the financing repayment amount was 0.12 billion yuan, resulting in a net buy of 3.92 million yuan [1] Group 2 - In terms of securities lending, there were no shares sold or net sold on that day [2]

Group 1 - The core point of the article highlights the financing activities of Innotec, indicating a net sell-off in the recent trading days [1] - On July 29, Innotec had a financing buy amount of 0.14 billion, ranking 1104th in the market, with a financing repayment amount of 0.18 billion, resulting in a net sell of 4.0711 million [1] - Over the last three trading days (July 25-29), Innotec recorded financing buys of 0.29 billion, 0.18 billion, and 0.14 billion respectively [1] Group 2 - In terms of securities lending, on the same day, there were no shares sold or net sold [2]

Core Viewpoint - The company has successfully completed its share repurchase plan, acquiring a total of 2,112,740 shares, which represents 1.5483% of its total share capital, with a total expenditure of approximately RMB 78 million [4][5]. Group 1: Share Repurchase Approval and Plan - On August 2, 2024, the company’s board approved a share repurchase plan, allowing for a maximum repurchase price of RMB 50.00 per share, with a total repurchase amount between RMB 50 million and RMB 100 million [2]. - Following the annual equity distribution for 2024, the maximum repurchase price was adjusted to RMB 49.45 per share [3]. Group 2: Implementation of Share Repurchase - The first share repurchase occurred on September 6, 2024, with ongoing disclosures of repurchase progress in accordance with relevant regulations [4]. - The repurchase was executed through the Shanghai Stock Exchange, with the highest transaction price at RMB 45.37 per share and the lowest at RMB 28.62 per share [4]. Group 3: Financial Impact and Shareholder Rights - The funds used for the repurchase were from the company’s own resources, ensuring no significant impact on its operational activities or financial status [5]. - The repurchased shares will not have voting rights or profit distribution rights during the holding period and will be used for future employee stock ownership plans or equity incentives [5].

证券代码：688253 证券简称：英诺特 公告编号：2025-032 北京英诺特生物技术股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/8/3，由公司实际控制人叶逢光先生、张秀杰 | | | | | --- | --- | --- | --- | --- | | | 女士提议 | | | | | 回购方案实施期限 | 年 8 月 2 年 月 1 日 | 2024 | 日~2025 | 8 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | 回购价格上限 | 49.45元/股 | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | □用于转换公司可转债 | | | | | | □为维护公司价值及股东权益 | | | | | 实际回购股数 | 211.2740万股 | | | | | 实际回购股数占总股本比例 | 1.5483% | | | | | 实际回购金额 | ...

证券代码：688253 证券简称：英诺特 公告编号：2025-031 北京英诺特生物技术股份有限公司关于公司及子公 司近期获得资质情况的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上述资质的取得，拓宽了公司产品的种类，进一步提高了公司的市场拓展能 力及核心竞争力。 三、风险提示 上述产品的实际销售受到市场需求、市场竞争以及公司市场推广效果等多种 因素影响，利润贡献具有不确定性，尚无法预测上述产品对公司未来经营业绩的 影响。敬请广大投资者谨慎投资、注意投资风险。 特此公告。 北京英诺特生物技术股份有限公司董事会 2025 年 7 月 19 日 一、公司及子公司近期获得资质的基本情况 北京英诺特生物技术股份有限公司（以下简称"公司"）全资子公司英诺特 （唐山）生物技术有限公司（以下简称"唐山英诺特"）近期新取得产品资质 1 项，具体情况如下表所示： | 获批主 | 产品名称 | 注册证号（备 | 发证日期 | 有效期至 | | --- | --- | --- | --- | --- | | 体 | | 案号） ...

| 序 | 获批主 | | | 产品名称 | | | 注册证号（备案 | 发证日期 | 有效期至 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 体 | | | | | | 号） | | | | 美国 | FDA | 510（k）产品文号 | 1 | 项 | | | | | | | 1 | 唐山英 诺特 | Innovita | Flu | A/B （甲型流感病毒/乙型流感病毒抗原 | Antigen | Rapid Test | K250398 | 2025/7/3 | 长期 | | | | 检测试剂盒） | | | | | | | | 二、对公司的影响 证券代码：688253 证券简称：英诺特 公告编号：2025-030 北京英诺特生物技术股份有限公司关于公司及子公 司近期获得资质情况的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、公司及子公司近期获得资质的基本情况 北京英诺特生物技术股份有限公司（以下简称" ...